Service de rhumatologie, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Antoine, Sorbonne Université, Inserm UMRS_938, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
Service de rhumatologie, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Antoine, Sorbonne Université, Inserm UMRS_938, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
Joint Bone Spine. 2020 Dec;87(6):548-555. doi: 10.1016/j.jbspin.2020.09.004. Epub 2020 Sep 12.
To establish recommendations for pharmacological treatment of knee osteoarthritis specific to France.
On behalf of the French Society of Rheumatology (SFR), a bibliography group analyzed the literature on the efficacy and safety of each pharmacological treatment for knee osteoarthritis. This group joined a multidisciplinary working group to draw up recommendations. Strength of recommendation and quality of evidence level were assigned to each recommendation. A review committee gave its level of agreement.
Five general principles were established: 1) need to combine pharmacological and non-pharmacological treatments, 2) personalization of treatment, 3) symptomatic and/or functional aim of pharmacological treatments, 4) need to regularly re-assess the treatments and 5) discussion about arthroplasty if medical treatment fails. Six recommendations involved oral treatments: 1) paracetamol should not necessarily be prescribed systematically and/or continuously, 2) NSAIDs, possibly as first-line, 3) weak opioids, 4) strong opioids, 5) symptomatic slow-acting drugs of osteoarthritis, and 6) duloxetine (off-label use). Two recommendations involved topical agents (NSAIDs and capsaicin<1%). Three recommendations involved intra-articular treatments: corticosteroid or hyaluronic acid injections that can be proposed to patients. The experts did not draw a conclusion about the benefits of platelet-rich plasma injections.
These are the first recommendations of the SFR on the pharmacological treatment of knee osteoarthritis.
针对法国,制定膝关节骨关节炎的药物治疗建议。
代表法国风湿病学会(SFR),一个文献小组分析了每种治疗膝关节骨关节炎的药物的疗效和安全性文献。该小组加入了一个多学科工作组来制定建议。为每个建议分配了推荐强度和证据质量等级。审查委员会表示同意。
确立了五项基本原则:1)需要将药物和非药物治疗相结合,2)治疗的个性化,3)药物治疗的症状和/或功能目标,4)需要定期重新评估治疗方法,5)如果药物治疗失败,讨论关节置换。有六项涉及口服治疗的建议:1)扑热息痛不一定需要系统和/或连续处方,2)非甾体抗炎药,可能作为一线药物,3)弱阿片类药物,4)强阿片类药物,5)治疗骨关节炎的症状性慢作用药物,6)度洛西汀(标签外使用)。有两项涉及局部药物(非甾体抗炎药和辣椒素<1%)的建议。有三项涉及关节内治疗的建议:可以向患者推荐皮质类固醇或透明质酸注射。专家对富血小板血浆注射的益处没有得出结论。
这是 SFR 关于膝关节骨关节炎药物治疗的第一批建议。